Addressing the Challenge of Defining Valid Proteomic Biomarkers and Classifiers

BMC Bioinformatics

Volumn 11, Issue , 2010, Pages

  Dakna, Mohammed ^a   Harris, Keith ^b   Kalousis, Alexandros ^c   Carpentier, Sebastien ^d   Kolch, Walter ^b,e   Schanstra, Joost P ^f,g   Haubitz, Marion ^h   Vlahou, Antonia ^j   Mischak, Harald ^a,i   Girolami, Mark ^k  

^a MOSAIQUES DIAGNOSTICS GMBH   (Germany)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF GENEVA   (Switzerland)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e Food Science and Veterinary Medicine   (Ireland)

^f INSERM   (France)

^g UNIVERSITÉ DE TOULOUSE   (France)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ UNIVERSITY OF GLASGOW   (United Kingdom)

^j BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSIS AND PROGNOSIS; MULTIPLE TESTING; NUMBER OF SAMPLES; PROTEOMIC BIOMARKERS; ROUTINE ANALYSIS; SAMPLE SIZE ESTIMATION; STATISTICAL DATAS; VALIDATED PLATFORM;

BODY FLUIDS; LEARNING ALGORITHMS;

DIAGNOSIS;

BIOLOGICAL MARKER;

ADULT; ALGORITHM; ARTICLE; CAPILLARY ELECTROPHORESIS; FEMALE; HUMAN; MALE; MASS SPECTROMETRY; METHODOLOGY; PROTEOMICS; REFERENCE VALUE; SAMPLE SIZE; URINE;

ADULT; ALGORITHMS; BIOLOGICAL MARKERS; ELECTROPHORESIS, CAPILLARY; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; PROTEOMICS; REFERENCE VALUES; SAMPLE SIZE; YOUNG ADULT;

EID: 78650761359     PISSN: None     EISSN: 14712105     Source Type: Journal    
DOI: 10.1186/1471-2105-11-594     Document Type: Article

References (51)

1. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006, 24(8):971-83. [Rifai1, Nader Gillette, Michael A Carr, Steven A Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review United States Nature biotechnology Nat Biotechnol. 2006 Aug;24(8):971-83.], 10.1038/nbt1235, 16900146.
2. Listgarten J, Emili A. Practical proteomic biomarker discovery: taking a step back to leap forward. Drug Discov Today 2005, 10(23-24):1697-702. 10.1016/S1359-6446(05)03645-7, 16376831.
3. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359(9306):572-7. 10.1016/S0140-6736(02)07746-2, 11867112.
4. McLerran D, Grizzle WE, Feng Z, Thompson IM, Bigbee WL, Cazares LH, Chan DW, Dahlgren J, Diaz J, Kagan J, Lin DW, Malik G, Oelschlager D, Partin A, Randolph TW, Sokoll L, Srivastava S, Thornquist M, Troyer D, Wright GL, Zhang Z, Zhu L, Semmes OJ. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem 2008, 54:53-60. 10.1373/clinchem.2007.091496, 18024530.
5. Diamandis EP. Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics?. Clin Chem 2003, 49(8):1272-5. 10.1373/49.8.1272, 12881441.
6. Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 2005, 5(2):142-9. 10.1038/nrc1550, 15685197.
7. Mischak H, Apweiler R, Banks RE, Conaway M, Coon J, Dominiczak A, Ehrich JHH, Fliser D, Girolami M, Hermjakob H, Hochstrasser D, Jankowski J, Julian BA, Kolch W, Massy ZA, Neusuess C, Novak J, Peter K, Rossing K, Schanstra J, Semmes OJ, Theodorescu D, Thongboonkerd V, Weissinger EM, Van Eyk JE, Yamamoto T. Clinical proteomics: A need to define the field and to begin to set adequate standards. PROTEOMICS - Clinical Applications 2007, 1(2):148-156. 10.1002/prca.200600771, 21136664., http://dx.doi.org/10.1002/prca.200600771
8. Decramer S, Gonzalez de Peredo A, Breuil B, Mischak H, Monsarrat B, Bascands JL, Schanstra JP. Urine in clinical proteomics. Mol Cell Proteomics 2008, 7(10):1850-62. 10.1074/mcp.R800001-MCP200, 18667409.
9. Fliser D, Novak J, Thongboonkerd V, Argiles A, Jankowski V, Girolami MA, Jankowski J, Mischak H. Advances in Urinary Proteome Analysis and Biomarker Discovery. J Am Soc Nephrol 2007, 18(4):1057-1071. 10.1681/ASN.2006090956, 17329573., http://jasn.asnjournals.org/cgi/content/abstract/18/4/1057
10. Haubitz M, Good DM, Woywodt A, Haller H, Rupprecht H, Theodorescu D, Dakna M, Coon JJ, Mischak H. Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis. Mol Cell Proteomics 2009, 8(10):2296-307. 10.1074/mcp.M800529-MCP200, 2758757, 19564150.
11. Good DM, Zürbig P, Argilés N, Bauer HW, Behrens G, Coon JJ, Dakna M, Decramer S, Delles C, Dominiczak AF, Ehrich JHH, Eitner F, Fliser D, Fromm-berger M, Ganser A, Girolami MA, Golovko I, Gwinner W, Haubitz M, Herget-Rosenthal S, Jankowski J, Jahn H, Jerums G, Julian BA, Kellmann M, Kliem V, Kolch W, Krolewski AS, Luppi M, Massy Z, Melter M, Neusüss C, Novak J, Peter K, Rossing K, Rupprecht H, Schanstra JP, Schiffer E, Stolzenburg JU, Tarnow L, Theodorescu D, Thongboonkerd V, Vanholder R, Weissinger EM, Mischak H, Schmitt-Kopplin P. Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease. Molecular and Cellular Proteomics 2010, 9(11):2424-2437. 10.1074/mcp.M110.001917, 20616184., http://www.mcponline.org/content/9/11/2424.abstract
12. Mischak H, Allmaier G, Apweiler R, Attwood T, Baumann M, Benigni A, Bennett SE, Bischo R, Bongcam-Rudloff E, Capasso G, Coon JJ, DHaese P, Dominiczak AF, Dakna M, Dihazi H, Ehrich JH, Fernandez-Llama P, Fliser D, Frokiaer J, Garin J, Girolami M, Hancock WS, Haubitz M, Hochstrasser D, Holman RR, Ioannidis JPA, Jankowski J, Julian BA, Klein JB, Kolch W, Luider T, Massy Z, Mattes WB, Molina F, Monsarrat B, Novak J, Peter K, Rossing P, Sanchez-Carbayo M, Schanstra JP, Semmes OJ, Spasovski G, Theodorescu D, Thongboonkerd V, Vanholder R, Veenstra TD, Weissinger E, Yamamoto T, Vlahou A. Recommendations for Biomarker Identification and Qualification in Clinical Proteomics. Science Translational Medicine 2010, 2(46):46ps42. 10.1126/scitranslmed.3001249, 20739680., http://stm.sciencemag.org/content/2/46/46ps42.abstract
13. Alonzo TA, Kittelson JM. A novel design for estimating relative accuracy of screening tests when complete disease verification is not feasible. Biometrics 2006, 62(2):605-12. [Alonzo, Todd A Kittelson, John M R01 GM54438/GM/NIGMS NIH HHS/United States Comparative Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't United States Bio-metrics Biometrics. 2006 Jun;62(2):605-12.], 10.1111/j.1541-0420.2005.00445.x, 16918926.
14. Buzoianu M, Kadane JB. Adjusting for verification bias in diagnostic test evaluation: a Bayesian approach. Stat Med 2008, 27:2453-2473. 10.1002/sim.3099, 17979150.
15. Page JH, Rotnitzky A. Estimation of the disease-specific diagnostic marker distribution under verification bias. Computational Statistics and Data Analysis 2009, 53(3):707-717., http://www.sciencedirect.com/science/article/B6V8V-4SX9FTT-1/2/a708b210a358c83a359bd1c2ca7bef7f
16. Mischak H, Coon JJ, Novak J, Weissinger EM, Schanstra JP, Dominiczak AF. Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments. Mass Spectrom Rev 2009, 28(5):703-24. 10.1002/mas.20205, 2720435, 18973238.
17. Jantos-Siwy J, Schiffer E, Brand K, Schumann G, Rossing K, Delles C, Mischak H, Metzger J. Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J Proteome Res 2009, 8:268-81. 10.1021/pr800401m, 19012428.
18. Wang P, Tang H, Zhang H, Whiteaker J, Paulovich AG, Mcintosh M. Normalization regarding non-random missing values in high-throughput mass spectrometry data. Pac Symp Biocomput 2006, 315-326. full_text, 17094249.
19. Helsel R. Nondetects and data analysis: statistics for censored environmental data. 2005, New York: Wiley-Interscience.
20. Taylor S, Pollard K. Hypothesis tests for point-mass mixture data with application to 'omics data with many zero values. Stat Appl Genet Mol Biol 2009, 8:Article 8.
21. Broadhurst D, Kell D. Statistical strategies for avoiding false discoveries in metabolomics and related experiments. Metabolomics 2006, 2(4):171-196., http://dx.doi.org/10.1007/s11306-006-0037-z
22. Dakna M, He Z, Yu WC, Mischak H, Kolch W. Technical, bioinformatical and statistical aspects of liquid chromatography-mass spectrometry (LC-MS) and capillary electrophoresis-mass spectrometry (CE-MS) based clinical proteomics: a critical assessment. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:1250-1258. 10.1016/j.jchromb.2008.10.048, 19010091.
23. Oberg AL, Vitek O. Statistical Design of Quantitative Mass Spectrometry-Based Proteomic Experiments. Journal of Proteome Research 2009, 8(5):2144-2156. 10.1021/pr8010099, 19222236.
24. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society. Series B (Methodological) 1995, 57:289-300., http://vorlon.case.edu/~sray/mlrg/controlling_fdr_benjamini95.pdf
25. Hemelrijk J. Note on Wilcoxon's Two-Sample Test when Ties are Present. Annals of Mathematical Statistics 1952, 23:133-135.
26. Soares AJ, Santos M, Trugilho M, Neves-Ferreira A, Perales J, Domont G. Differential proteomics of the plasma of individuals with sepsis caused by Acinetobacter baumannii. Journal of Proteomics 2009, 73(2):267-278. 10.1016/j.jprot.2009.09.010, 19782774., http://www.sciencedirect.com/science/article/B8JDC-4X9NVD1-1/2/e97759e56b52f471a9361b9d05d3072b
27. Matsubara J, Ono M, Honda K, Negishi A, Ueno H, Okusaka T, Furuse J, Furuta K, Sugiyama E, Saito Y, Kaniwa N, Sawada J, Shoji A, Sakuma T, Chiba T, Saijo N, Hirohashi S, Yamada T. Survival Prediction for Pancreatic Cancer Patients Receiving Gemcitabine Treatment. Molecular and Cellular Proteomics 2010, 9(4):695-704. 10.1074/mcp.M900234-MCP200, 20061307., http://www.mcponline.org/content/9/4/695.abstract
28. Ma Y, Peng J, Huang L, Liu W, Zhang P, Qin H. Searching for serum tumor markers for colorectal cancer using a 2-D DIGE approach. Electrophoresis 2009, 30(15):2591-2599. 10.1002/elps.200900082, 19637221.
29. Altman DMD, TN B, MJ G. Statistics with Confidence: Confidence intervals and statistical guidelines. 2000, London: BMJ Books, 2.
30. Cairns DA, Barrett JH, Billingham LJ, Stanley AJ, Xi-narianos G, Field JK, Johnson PJ, Selby PJ, Banks RE. Sample size determination in clinical proteomic profiling experiments using mass spectrometry for class comparison. Proteomics 2009, 9:74-86. 10.1002/pmic.200800417, 19053145.
31. Jackson D, Herath A, Swinton J, Bramwell D, Chopra R, Hughes A, Cheeseman K, Tonge R. Considerations for powering a clinical proteomics study: Normal variability in the human plasma proteome. PROTEOMICS - CLINICAL APPLICATIONS 2009, 3(3):394-407.
32. Efron B, Tibshirani R. An Introduction to the Bootstrap. 1993, Boca Raton: Chapman & Hall/CRC.
33. Strimmer K. A unified approach to false discovery rate estimation. BMC Bioinformatics 2008, 9:303. 10.1186/1471-2105-9-303, 2475539, 18613966.
34. Lesaffre E, Scheys I, Frohlich J, Bluhmki E. Calculation of power and sample size with bounded outcome scores. Stat Med 1993, 12:1063-1078.
35. Walters SJ. Sample size and power estimation for studies with health related quality of life out-comes: a comparison of four methods using the SF-36. Health Qual Life Outcomes 2004, 2:26. 10.1186/1477-7525-2-26, 421748, 15161494.
36. Lin WJ, Hsueh HM, Chen JJ. Power and sample size estimation in microarray studies. BMC Bioinformatics 2010, 11:48. 10.1186/1471-2105-11-48, 2837028, 20100337.
37. Mukherjee S, Tamayo P, Rogers S, Rifkin R, Engle A, Campbell C, Golub TR, Mesirov JP. Estimating dataset size requirements for classifying DNA microarray data. J Comput Biol 2003, 10(2):119-42. 10.1089/106652703321825928, 12804087.
38. Kenneth RH, Caimiao W. Learning Curves in Classification With Microarray Data. Seminars in oncology 2010, 37:65-68. 10.1053/j.seminoncol.2009.12.002, 20172367.
39. Dobbin KK, Zhao Y, Simon RM. How large a training set is needed to develop a classifier for microarray data?. Clin Cancer Res 2008, 14:108-14. 10.1158/1078-0432.CCR-07-0443, 18172259.
40. Dobbin KK, Simon RM. Sample size planning for developing classifiers using high-dimensional DNA microarray data. Biostatistics 2007, 8:101-117. 10.1093/biostatistics/kxj036, 16613833.
41. Braga-Neto UM, Dougherty ER. Is cross-validation valid for small-sample microarray classification?. Bioinformatics 2004, 20(3):374-80. 10.1093/bioinformatics/btg419, 14960464.
42. Molinaro AM, Simon R, Pfeiffer RM. Prediction error estimation: a comparison of resampling methods. Bioinformatics 2005, 21(15):3301-7. 10.1093/bioinformatics/bti499, 15905277.
43. Dudoit S, van der Laan M. Multiple Testing Procedures with Applications to Genomics. 2008, New York: Springer.
44. Hogg R, Tannis E. Probability and Statistical Inference. 2010, Prentice Hall: Pearson, 8.
45. Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, Just I, Mischak H, Frierson HF. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 2006, 7(3):230-40. 10.1016/S1470-2045(06)70584-8, 16510332.
46. Wittke S, Mischak H, Walden M, Kolch W, Radler T, Wiedemann K. Discovery of biomarkers in human urine and cerebrospinal fluid by capillary electrophoresis coupled to mass spectrometry: towards new diagnostic and therapeutic approaches. Electrophoresis 2005, 26(7-8):1476-87. 10.1002/elps.200410140, 15765478.
47. Neuhoff N, Kaiser T, Wittke S, Krebs R, Pitt A, Bur-chard A, Sundmacher A, Schlegelberger B, Kolch W, Mischak H. Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. Rapid Commun Mass Spectrom 2004, 18(2):149-56. 10.1002/rcm.1294, 14745763.
48. Coon JJ, Zurbig P, Dakna M, Dominiczak AF, Decramer S, Fliser D, Frommberger M, Golovko I, Good DM, Herget-Rosenthal S, Jankowski J, Julian BA, Kellmann M, Kolch W, Massy Z, Novak J, Rossing K, Schanstra JP, Schiffer E, Theodorescu D, Vanholder R, Weissinger EM, Mischak H, Schmitt-Kopplin P. CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl 2008, 2:964. 10.1002/prca.200800024, 2815342, 20130789.
49. Alkhalaf A, Zürbig P, Bakker SJL, Bilo HJG, Cerna M, Fischer C, Fuchs S, Janssen B, Medek K, Mischak H, Roob JM, Rossing K, Rossing P, Rychlík I, Sourij H, Tiran B, Winklhofer-Roob BM, Navis GJ, . for the PREDICTIONS Group Multicentric Validation of Proteomic Biomarkers in Urine Specific for Diabetic Nephropathy. PLoS ONE 2010, 5(10):e13421. 10.1371/journal.pone.0013421, 2958112, 20975990, for the PREDICTIONS Group., http://dx.doi.org/10.1371%2Fjournal.pone.0013421
50. Maahs DM, Siwy J, Argilés N, Cerna M, Delles C, Dominiczak AF, Gayrard N, Iphöfer A, Jänsch L, Jerums G, Medek K, Mischak H, Navis GJ, Roob JM, Rossing K, Rossing P, Rychlík I, Schiffer E, Schmieder RE, Wascher TC, Winklhofer-Roob BM, Zimmerli LU, Zürbig P, Snell-Bergeon JK. Urinary Collagen Fragments Are Significantly Altered in Diabetes: A Link to Pathophysiology. PLoS ONE 2010, 5(9):e13051. 10.1371/journal.pone.0013051, 2946909, 20927192., http://dx.doi.org/10.1371%2Fjournal.pone.0013051
51. R Development Core Team R: A Language and Environment for Statistical Computing. 2010, R Foundation for Statistical Computing, Vienna, Austria, [ISBN 3-900051-07-0], R Development Core Team., http://www.R-project.org